The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
23 janv. 2024 09h29 HE
|
Agile Therapeutics, Inc.
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
12 déc. 2023 08h01 HE
|
Agile Therapeutics, Inc.
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the...
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 08h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter...
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
26 oct. 2023 08h05 HE
|
Agile Therapeutics, Inc.
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it...
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2023 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to...
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 08h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari...
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
09 août 2023 08h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to...
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
26 juil. 2023 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before...
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
26 juin 2023 08h01 HE
|
Agile Therapeutics, Inc.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities...
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
23 juin 2023 12h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today praised the Executive Order issued by President Biden that addresses...